Graft-versus-Host disease after bone marrow transplantation for thalassemia: An analysis of incidence and risk factors

Transplantation

Volumn 63, Issue 6, 1997, Pages 854-860

  Gaziev, Djavid ^a   Polchi, Paola ^a   Galimberti, Maria ^a   Angelucci, Emanuele ^a   Giardini, Claudio ^a   Baronciani, Donatella ^a   Erer, Buket ^a   Lucarelli, Guido ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; THALASSEMIA;

ADOLESCENT; ADULT; AGE FACTORS; ALANINE TRANSAMINASE; BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; INFANT; MALE; NUCLEAR FAMILY; ODDS RATIO; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX CHARACTERISTICS; SPLENOMEGALY; TIME FACTORS; TISSUE DONORS;

EID: 0030968020     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199703270-00011     Document Type: Article

References (47)

1. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417.
2. Weatherall D. Bone marrow transplantation for thalassemia and other inherited disorders of hemoglobin. Blood 1992; 80: 1379.
3. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840.
4. Lucarelli G, Giardini C, Baronciani D. Bone marrow transplantation in thalassemia. Semin Hematol 1995; 4: 297.
5. Deeg HJ, Henslee-Downey PJ. Management of acute graft-versus-host disease. Bone Marrow Transplant 1990; 6: 1.
6. Parr MD, Messino MJ, McIntyre W. Allogeneic bone marrow transplantation: procedures and complications. Am J Hosp Pharm 1991; 48: 127.
7. Vogelsang GB, Morris LE. Prevention and management of graft-versus-host disease: practical recommendations. Drug 1993; 45: 668.
8. Atkinson K. Chronic graft-versus-host disease: review. Bone Marrow Transplant 1990; 5: 69.
9. Gale RP. Graft-versus-host disease. Immunol Rev 1985; 88: 194.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA- matched sibling donors. Transplantation 1974; 18: 295.
11. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-versus-host reaction in human recipients of marrow from HLA-matched sibling donors. Transplant Proc 1974; 6: 367.
12. Ferrara JLM, Deeg HJ. Mechanisms of disease: graft-versus-host disease. N Engl J Med 1991; 304: 667.
13. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267.
14. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397.
15. Bross DS, Tutschka PJ, Farmer ER, et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 6: 1265.
16. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporin and methotrexate. Blood 1992; 7: 1838.
17. Storb R, Prentice RC, Shulman HM, et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461.
18. Ringden O, Paulin T, Lonnqvist B, Nilsson B. An analysis of factors predisposing to chronic graft-versus-host disease. Exp Hematol 1985; 13: 1062.
19. Neiderwieser D, Pepe M, Storb B, Witherspoon RP, Longton G, Sullivan KM. Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. Bone Marrow Transplant 1989; 4: 151.
20. Atkinson K, Horowitz M, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 12: 2459.
21. Sanders JE, Whitehead J, Storb R, et al. Bone marrow transplantation experience for children with aplastic anemia. Pediatrics 1986; 77: 179.
22. Ramsey NKC, Kersey JH, Robison LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306: 392.
23. Eisner MD, August CS. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following paediatric bone marrow transplantation. Bone Marrow Transplant 1995; 15: 663.
24. Galimberti M, Polchi P, Lucarelli G, et al. A comparative trial of posttransplant immunosuppression in patients transplanted for thalassemia: cyclosporin alone versus cyclosporin, cyclophosphamide, and methotrexate. Transplantation 1988; 3: 566.
25. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832.
26. Shulman HM, Sullivan KM, Weiden PC, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204.
27. Siegel J, ed. Statistix: version 4.0 user's manual. Tallahassee, FL: Analytical Software, 1992.
28. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
29. Wilcoxon F. Individual comparison by ranking methods. Biometr Bull 1945; 1: 80.
30. Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporin, methotrexate, and prednisone compared with cyclosporin and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 17: 1225.
31. Storb R, Sanders JE, Pepe M, et al. Graft-versus-host disease prophylaxis with methotrexate/cyclosporin in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. Blood 1991; 4: 1144.
32. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporin versus cyclosporin alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up for a controlled trial. Blood 1989; 73: 1729.
33. Forman SJ, Blume KG, Krance RA, et al. A prospective randomized study of acute-graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporin A/prednisone. Transplant Proc 1987; 19: 2605.
34. Lucarelli G, Clift R, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 5: 2082.
35. Saunders JE, Flournoy N, Thomas ED, et al. Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse and graft-versus-host disease. Med Pediatr Oncol 1985; 13: 165.
36. Brodehl J. Consensus statements on the optimal use of cyclosporin in paediatric patients. Transplant Proc 1994; 26: 2759.
37. Rodman JH, Stricklin L, Pederson A, et al. Cyclosporin clearance in paediatric patients undergoing bone marrow transplant using monoclonal whole blood assay [Abstract]. Pharmacotherapy 1994; 14: 369.
38. Baughan ASJ, Worsley AM, McCarthy DM, et al. Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukemia: the influence of previous splenectomy. Br J Haematol 1984; 56: 445.
39. Michallet M, Corront B, Bosson JL, et al. Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients. Bone Marrow Transplant 1991; 8: 13.
40. Ringden O, Nilsson B. Death by graft-versus-host disease is associated with HLA- mismatch, high recipient age, low marrow cell dose and splenectomy. Transplantation 1985; 40: 39.
41. Gratwohl A, Gluckman E, Goldman J, Zwaan F. Effect of splenectomy before bone marrow transplantation on survival in chronic granulocyte leukemia. Lancet 1985; 2: 1290.
42. Kalhs P, Schwarzinger I, Anderson G, et al. A retrospective analysis of the long-term effect of splenectomy on late infections, graft- versus-host disease, relapse, and survival after allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995; 5: 2028.
43. Appleton AL, Sviland L. Pathogenesis of GVHD: role of herpes viruses. Bone Marrow Transplant 1993; 11: 349
44. Schwinghammer TL, Bloom EJ, Rosenfeld CS, Wilson JW, Przepiorka D, Shaddnek RK. High-dose cyclosporin and corticosteroids for prophylaxis of acute and chronic graft-versus-host disease. Bone Marrow Transplant 1995; 16: 147.
45. Lonnqvist B, Aschan J, Ljungman P, Ringden O. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease [Letter]. Br J Haematol 1990; 74: 547.
46. Tsoi MS, Storb R, Dobbs S, Thomas ED. Specific suppressor cells in graft-host tolerance of HLA-identical marrow transplant. Nature 1981; 292: 355.
47. Kattamis ChA, Kattamis CK. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination. Semin Hematol 1995; 4: 269.